Abstract
The importance of tight blood pressure (BP) control has been established. We performed cross-sectional studies on the current status of BP control and the prescription and efficacy of antihypertensive drugs in hypertensive patients in Japan. The data were also evaluated in subgroups with or without diabetes mellitus (DM) and in winter and summer. Analyses were performed on the collected data of 12,437 treated hypertensive patients in winter and 5,972 in summer 2002. In winter, 50.3% of patients received calcium channel blockers (CCBs), 15.3% received angiotensin converting enzyme inhibitors (ACEIs) and 11.0% received angiotensin receptor blockers (ARBs). In the patients receiving monotherapy, 69% of patients received a CCB, 13% an ACEI and 11.0% an ARB. A total of 2,918 patients received combination therapy, and CCBs were the most frequently (89.6%) prescribed component of such therapy. Prescriptions of β-blockers (BBs) decreased and those of CCBs and diuretics (D) increased with age (p<0.001). The rate of patients with adequately controlled BP less than 140/90 mmHg was 40.3% in the CCB group, 37.6% in the D group, and 36.9% in the BB group (p<0.001). In patients receiving combination therapy, those with CCB+D had the best rate of BP control (40.7%). The rate of patients with adequately controlled BP was lower in winter than in summer at both a target BP of 140/90 mmHg (36.2% vs. 43.8%, p<0.001) and a target BP of 130/85 mmHg in patients younger than 60 years old (15.5% vs. 18.6%, p<0.02). In diabetic patients, the target BP (130/80 mmHg) was achieved in only 11.3%, which was lower (p<0.05) than the rate in non-diabetic patients (13.1%). In conclusion, the present cross-sectional study showed that CCBs were the most frequently prescribed agent for the treatment of hypertension in Japan. The rate of adequate BP control was less than 50% and was even worse in patients with DM and in winter. Our results indicate that physicians should treat hypertension more intensively to achieve the target BP.
Similar content being viewed by others
Article PDF
References
Staessen JA, Wang JG, Thijs L : Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305–1315.
Staessen JA, Wang JG, Thijs L : Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–1076.
Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trailists' Collaboration : Effect of ACE inhibitors, calcium antagonists, and other blood-pressure–lowering drugs: result of prospectively designed overviews of randomized trials. Lancet 2000; 356: 1955–1964.
Chobanian AV, Bakris GL, Black HR, et al: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560–2572.
Saruta T : Current status of calcium antagonists in Japan. Am J Cardiolol 1998; 12: 32R–34R.
Guidelines Committee : 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. Hypertension 2003; 21: 1011–1053.
Mori H, Yamamoto H, Kuwashima M, et al: How does deep breathing affect office blood pressure and pulse rate? Hypertens Res 2005; 28: 499–504.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients radomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981.
Julius S, Kjeldsen SE, Weber M, et al, for the VALUE Trial Group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based valsartan or amlodipine: the VALUE Randomised Trial. Lancet 2004; 363: 2022–2031.
Borghi C, Dormi A, D'Addato S, Gaddi A, Ambrosioni E : Trend in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens 2004; 22: 1707–1716.
Godley PJ, Maue SK, Farrelly EW, Frech F : The need for improved medical management of patients with concomitant hypertension and type 2 diabetes mellitus. Am J Manag Care 2005; 11: 206–210.
Kramer H, Han C, Post W, et al: Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA). Am J Hypertens 2004; 17: 963–970.
Whelton PK, He J, Munter P : Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. J Hum Hypertens 2004; 18: 545–551.
Pittrow D, Kirch W, Bramlage P, et al: Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004; 60: 135–142.
Mancia G, Pessina AC, Trimarco B, Grassi G, SILVIA (Studio Italiano Longitudinale sulla Valutazione della Ipertensione Arteriosa nel 2000) Study Group: Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22: 2387–2396.
Whelton PK, Beevers DG, Sonkodi S : Strategy for improvement of awareness, treatment and control of hypertension: result of a panel discussion. J Hum Hypertens 2004; 18: 563–565.
Al Khaja KA, Sequeira RP, Damanhori AH : Pharmacotherapy and blood pressure control in elderly hypertensives in a primary care setting in Bahrain. Aging Clin Exp Res 2004; 16: 319–325.
Fuchs FD : Blood pressure–lowering drugs: essential therapy for some patients with normal blood pressure. Expert Rev Cardiovasc Ther 2004; 2: 771–775.
Bannan LT, Beevers DG, Jackson SHD : Detecting hypertensive patients. Br Med J 1981; 1: 1211–1213.
Lusher TF, Vetter H, Siegenthaler W, Vetter W : Compliance in hypertension: facts and concepts. J Hypertens 1985; 3 ( Suppl 1): 3–9.
Ohkubo T, Obara T, Funahashi J, et al: Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: first report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) Study. Hypertens Res 2004; 27: 755–763.
Ornstein SM, Nietert PJ, Dickerson LM : Hypertension management and control in primary care: a study of 20 practice in 14 states. Pharmcotherapy 2004; 24: 500–507.
Andrade SE, Gurwitz JH, Field TS, et al: Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care 2004; 10: 481–486.
Ono A, Fujita T : Factors relating to inadequate control of blood pressure in hypertensive outpatients. Hypertens Res 2003; 26: 219–224.
Mainous AG 3rd, King DE, Garr DR, Pearson WS : Race, rural residence, and control of diabetes and hypertension. Ann Fam Med 2004: 2: 563–568.
Psaltopoulou T, Orfanos P, Naska A, Lenas D, Trichopoulos D, Trichopoulou A : Prevalence, awareness, treatment and control of hypertension in a general population sample of 26,913 adults in the Greek EPIC Study. Int J Epidemiol 2004; 33: 1345–1352.
Yamori Y, Longjian L, Lihong M, et al: Diet-related factors, educational level and blood pressure in a Chinese population sample: findings from the Japan–China cooperative research project. Hypertens Res 2002; 25: 559–564.
McInnes GT : How important is optimal blood pressure control? Clin Ther 2004; 26 ( Suppl A): A3–A11.
Ram CV : Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens 2004; 6: 569–577.
Bobrie G, Chatellier G, Genes N, et al: Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291: 1342–1349
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mori, H., Ukai, H., Yamamoto, H. et al. Current Status of Antihypertensive Prescription and Associated Blood Pressure Control in Japan. Hypertens Res 29, 143–151 (2006). https://doi.org/10.1291/hypres.29.143
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.29.143
Keywords
This article is cited by
-
Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis
High Blood Pressure & Cardiovascular Prevention (2023)
-
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study
Hypertension Research (2022)
-
Current antihypertensive treatment and treatment-resistant hypertension in Japanese patients with chronic kidney disease
Clinical and Experimental Nephrology (2022)
-
Cluster-randomized controlled trial for the early promotion of clinic visits for untreated hypertension
Hypertension Research (2021)
-
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Hypertension Research (2019)